经鼻给予S-MGB-364在结核分枝杆菌感染中显示抗结核活性并调节宿主免疫反应
在感染结核分枝杆菌(Mtb)的小鼠中,经鼻给予S-MGB-364或S-MGB-364非离子表面活性剂囊泡(NIV)包封制剂,肺部无毒,使分枝杆菌负荷下降约1 log cfu,降低促炎细胞因子/趋化因子表达,改变免疫细胞募集并减少中性粒细胞募集;S-MGB-364以二聚体形式强结合DNA,抑制Mtb拓扑异构酶I而非人源拓扑异构酶I。
要点
- 经鼻给予S-MGB-364或其NIV包封制剂在Mtb感染小鼠肺部无毒,分枝杆菌负荷下降约1 log cfu。
- S-MGB-364以二聚体形式强结合DNA,并抑制Mtb拓扑异构酶I而不抑制人源拓扑异构酶I。
- 在巨噬细胞中S-MGB-364或S-MGB-364-NIV未引起DNA损伤,γ-H2AX表达低。
核心结论
- 这些数据为S-MGBs作为新型抗结核治疗药物提供了体内概念验证。
研究设计与样本
- 在Mtb感染小鼠中评估经鼻给予S-MGB-364或S-MGB-364非离子表面活性剂囊泡(NIV)包封制剂的抗结核与宿主免疫效应,方法包括cfu计数、ELISA、组织学和流式细胞术。
- 采用天然质谱和紫外-可见热熔解测定检查DNA结合,并使用具代表性的Mtb与人拓扑异构酶I及旋转酶试验评估S-MGB对以DNA为中心的生物学事件的干扰。
主要发现
- S-MGB-364以二聚体形式强结合DNA,与DNA单独相比显著增加DNA:S-MGB复合物的稳定性。
- S-MGB-364抑制Mtb拓扑异构酶I的松弛作用,但不抑制人源拓扑异构酶I。
- 在巨噬细胞中,S-MGB-364或S-MGB-364-NIV未引起DNA损伤,表现为低γ-H2AX表达。
- 在Mtb感染小鼠肺部,经鼻给予S-MGB-364或S-MGB-364-NIV制剂无毒,并使分枝杆菌负荷下降约1 log cfu。
- 经鼻给予S-MGB-364或S-MGB-364-NIV降低促炎细胞因子/趋化因子表达,改变免疫细胞募集,并减少中性粒细胞募集。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previously, we evaluated the intracellular mycobactericidal activity of the minor groove binder, S-MGB-364 against the clinical Mycobacterium tuberculosis (Mtb) strain HN878 in macrophages. OBJECTIVES: To assess the mycobactericidal activity of S-MGB-364 in Mtb-infected mice. Further, we investigated a plausible DNA binding mechanism of action of S-MGB-364. METHODS: The anti-TB and host immune effects of intranasal S-MGB-364 or S-MGB-364 encapsulated in non-ionic surfactant vesicles (NIV) were assessed in Mtb-infected mice by cfu enumeration, ELISA, histology, and flow cytometry. DNA binding was examined using native mass spectrometry and UV-vis thermal melt determination. S-MGB interference with DNA-centric biological events was assessed using a representative panel of Mtb and human topoisomerase I, and gyrase assays. RESULTS: S-MGB-364 bound strongly to DNA as a dimer, significantly increasing the stability of the DNA:S-MGB complex compared with DNA alone. Moreover, S-MGB-364 inhibited the relaxation of Mtb topoisomerase I but not the human form. In macrophages, S-MGB-364 or S-MGB-364-NIV did not cause DNA damage as shown by the low γ-H2AX expression. Importantly, in the lungs, the intranasal administration of S-MGB-364 or S-MGB-364-NIV formulation in Mtb-infected mice was non-toxic and resulted in a ∼1 log cfu reduction in mycobacterial burden, reduced the expression of proinflammatory cytokines/chemokines, altered immune cell recruitment, and importantly reduced recruitment of neutrophils. CONCLUSIONS: Together, these data provide proof of concept for S-MGBs as novel anti-TB therapeutics in vivo.
引用
- Kieswetter NS, Ozturk M, Hlaka L, et al. Intranasally administered S-MGB-364 displays antitubercular activity and modulates the host immune response to Mycobacterium tuberculosis infection. J Antimicrob Chemother. 2022. PMID: 35084027. doi:10.1093/jac/dkac001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。